CDK4/6 inhibitors combined with endocrine therapy is the first-line standard treatment for advanced HR+/HER2- breast cancer patients without visceral crisis, but the optimal treatment regimen after progression remains unclear. This evidence concerns the gene ERBB2 and breast carcinoma.